FIELD: medicine.
SUBSTANCE: invention relates to peptides which can efficiently and specifically reactivate mutant p53 proteins. In particular, peptides which reactivate the mutant p53 protein, which can restore native folding of wild-type p53 protein and, hence, activity of tumor suppressors with respect to mutant p53 protein are disclosed.
EFFECT: such peptides can be suitable for treating various conditions and diseases in which p53 protein is mutated.
17 cl, 10 tbl, 12 ex, 21 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS | 2014 |
|
RU2721423C2 |
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
| SYNTHETIC MUTANT GENE RB (VARIANTS), SYNTHETIC MUTANT GENE P53, PLASMID (VARIANTS), MUTANT PROTEIN (VARIANTS), METHOD OF INHIBITION OF CELLULAR PROLIFERATION (VARIANTS), METHOD OF INDUCTION OF APOPTOSIS | 1995 |
|
RU2192431C2 |
| ANTIBODY WHICH BINDS A LINEAR EPITOPE OF HUMAN P53, AND USE THEREOF IN DIAGNOSIS | 2015 |
|
RU2741795C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| TREATMENTS OF CANCER EXPRESSING MUTANT EGF RECEPTORS | 2007 |
|
RU2429014C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF KIDNEY CANCER | 2017 |
|
RU2752322C2 |
| ANTIBODIES AGAINST FGFR3 AND METHODS OF THEIR APPLICATION | 2010 |
|
RU2568066C2 |
| MTS GENE, MUTATIONS OF THIS GENE AND METHODS OF DIAGNOSIS OF MALIGNANT TUMORS USING MTS GENE SEQUENCE | 1995 |
|
RU2164419C2 |
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2549678C2 |
